Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Peter Kubiak"'
Autor:
Kathrin Krüger, Lara Marleen Fricke, Elise-Marie Dilger, Annett Thiele, Kristina Schaubert, Dyon Hoekstra, Fedor Heidenreich, Anna Levke Brütt, Jona T. Stahmeyer, Alexander Stahmann, Anna-Lena Röper, Klaus-Peter Kubiak, Melissa Hemmerling, Anja Grau, Kerstin Eichstädt, Sabine Behrens, Christian Krauth
Publikováno v:
PLoS ONE, Vol 16, Iss 11 (2021)
Background Multiple sclerosis (MS) is the most common autoimmune inflammatory disease of the central nervous system in Europe, often causing severe physical, cognitive and emotional impairments. Currently, it is unclear whether the healthcare provisi
Externí odkaz:
https://doaj.org/article/295734c074a04964842256231dfed3f0
Autor:
David R. Shaffer, Matthew H. Taylor, Alvaro Pinto, Daniel Heinrich, Chung-Han Lee, Chinyere E. Okpara, Øyvind Krohn Tennøe, Mehmet Asim Bilen, Donald A. Richards, Jane Wu, Randy F. Sweis, Arpit Rao, Rodolfo F. Perini, Amishi Yogesh Shah, Allen Lee Cohn, Jay Courtright, James J. Hsieh, Emmett V. Schmidt, Sara Gunnestad Ribe, Alan D. Smith, Drew W. Rasco, Robert J. Motzer, Regina Gironés Sarrió, Christopher Di Simone, Sharad Jain, Musaberk Goksel, Peter Kubiak, Nicholas J. Vogelzang
Publikováno v:
LANCET ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Summary Background Despite advances in the first-line treatment of metastatic renal cell carcinoma (RCC), there is an unmet need for options to address disease progression during or after treatment with immune checkpoint inhibitors (ICIs). Pembrolizu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::560f50f96435950099b910b1a10224ee
https://doi.org/10.1016/s1470-2045(21)00241-2
https://doi.org/10.1016/s1470-2045(21)00241-2
Autor:
Christian Krauth, Klaus-Peter Kubiak, Kristina Schaubert, Anna Levke Brütt, Kathrin Krüger, Fedor Heidenreich, Anna-Lena Röper, Alexander Stahmann, Annett Thiele, Elise-Marie Dilger, Sabine Behrens, Anja Grau, Jona T. Stahmeyer, Lara Marleen Fricke, Melissa Hemmerling, Kerstin Eichstädt, Dyon Hoekstra
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 11 (2021)
PLoS ONE, Vol 16, Iss 11, p e0259855 (2021)
PLoS ONE, Vol 16, Iss 11 (2021)
PLoS ONE, Vol 16, Iss 11, p e0259855 (2021)
Background Multiple sclerosis (MS) is the most common autoimmune inflammatory disease of the central nervous system in Europe, often causing severe physical, cognitive and emotional impairments. Currently, it is unclear whether the healthcare provisi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1201f6f99cea005fbf3ddc1ad29bc7b
https://pubmed.ncbi.nlm.nih.gov/34762697
https://pubmed.ncbi.nlm.nih.gov/34762697
Autor:
Alan D. Smith, Antonio González-Martín, Eduardo Yanez, Bristi Basu, Hyun Cheol Chung, Peter Kubiak, Kevin Norwood, Hélène Senellart, Zarnie Lwin, Philippe A. Cassier, Razi Ghori, Esma Saada-Bouzid
Publikováno v:
Ovarian cancer.
Introduction/Background Lenvatinib, an antiangiogenic multiple receptor tyrosine kinase inhibitor, plus pembrolizumab, a programmed death-1 immune checkpoint inhibitor, demonstrated promising clinical benefit in a previous phase Ib/II trial across se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05c55229b7b64b1aaeb4197266daccd4
https://doi.org/10.1136/ijgc-2020-esgo.116
https://doi.org/10.1136/ijgc-2020-esgo.116
Autor:
Antonio González-Martín, Kevin Norwood, Zarnie Lwin, H.C. Chung, Eduardo Yanez, Bristi Basu, Alan D. Smith, P. A. Cassier, Esma Saada-Bouzid, Razi Ghori, Peter Kubiak, Hélène Senellart
Publikováno v:
Oral Plenary.
Introduction Lenvatinib, an antiangiogenic multiple receptor tyrosine kinase inhibitor, plus pembrolizumab, a programmed death-1 immune checkpoint inhibitor, demonstrated promising clinical benefit in a previous phase Ib/II trial across several cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26a0718bffa47dd64e4c1fa0996ba2d5
https://doi.org/10.1136/ijgc-2020-igcs.2
https://doi.org/10.1136/ijgc-2020-igcs.2
Autor:
Yukinori Minoshima, Alan D. Smith, Rodolfo F. Perini, Hiroki Ikezawa, Min Ren, Robert J. Motzer, Yusuke Adachi, Peter Kubiak, S.D. Li, Yasuhiro Funahashi, C.-H. Lee
Publikováno v:
Annals of Oncology. 31:S564-S565
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f7443e8084e1f969eda094e49015bb3
https://doi.org/10.1016/j.annonc.2020.08.791
https://doi.org/10.1016/j.annonc.2020.08.791
Autor:
R. Girones Sarrio, C.-H. Lee, Chinyere E. Okpara, Allen Lee Cohn, Emmett V. Schmidt, C. Di Simone, James J. Hsieh, Mehmet Asim Bilen, Arpit Rao, Alan D. Smith, Robert J. Motzer, David R. Shaffer, Alvaro Pinto, S. Gunnestad Ribe, Jane Wu, Peter Kubiak, Amishi Yogesh Shah
Publikováno v:
Annals of Oncology. 31:S558-S559
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c51cb51333d5cf91a44333c50f7c001c
https://doi.org/10.1016/j.annonc.2020.08.782
https://doi.org/10.1016/j.annonc.2020.08.782
Autor:
Chung-Han Lee, Robert J. Motzer, Peter Kubiak, Alan D. Smith, Alvaro Pinto, Sara Gunnestad Ribe, Arpit Rao, Jane Wu, David R. Shaffer, James J. Hsieh, Christopher DiSimone, Allen Lee Cohn, Amishi Yogesh Shah, Regina Gironés Sarrió, Emmett V. Schmidt, Chinyere E. Okpara, Mehmet Asim Bilen
Publikováno v:
Journal of Clinical Oncology. 39:e16542-e16542
e16542 Background: Immune checkpoint inhibitors (ICIs) are commonly used as first-line treatment for pts with advanced RCC. In the recent phase 3 CLEAR trial, LEN + PEMBRO showed improved objective response rate (ORR), progression-free survival (PFS)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4ea265b306ba94e8f69ea8b53672d49
https://doi.org/10.1200/jco.2021.39.15_suppl.e16542
https://doi.org/10.1200/jco.2021.39.15_suppl.e16542
Autor:
Hyun Cheol Cheol Chung, Zarnie Lwin, Carlos A. Gomez-Roca, Federico Longo, Eduardo Yanez, Eduardo Castanon Alvarez, Donna M. Graham, Mark Doherty, Philippe Cassier, Juanita Suzanne Lopez, Bristi Basu, Andrew Eugene Hendifar, Corinne Maurice-Dror, Sanjeev Singh Gill, Razi Ghori, Peter Kubiak, Fan Jin, Kevin Glen Norwood, Esma Saada-Bouzid
Publikováno v:
Journal of Clinical Oncology. 39:4030-4030
4030 Background: Lenvatinib, an anti-angiogenic multiple receptor tyrosine kinase inhibitor, in combination with the anti‒PD-1 antibody pembrolizumab, has demonstrated promising antitumor activity with manageable safety in the first- or second-line
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b6bdee561ddcc162bdc71861ce7300f
https://doi.org/10.1200/jco.2021.39.15_suppl.4030
https://doi.org/10.1200/jco.2021.39.15_suppl.4030
Autor:
Carlos A. Gomez-Roca, Eduardo Yanez, Seock-Ah Im, Eduardo Castanon Alvarez, Hélène Senellart, Mark Doherty, Javier Garcia-Corbacho, Juanita Suzanne Lopez, Bristi Basu, Corinne Maurice-Dror, Sanjeev Singh Gill, Razi Ghori, Peter Kubiak, Fan Jin, Kevin Glen Norwood, Hyun Cheol Cheol Chung
Publikováno v:
Journal of Clinical Oncology. 39:3564-3564
3564 Background: Pembrolizumab (pembro), an anti-PD-1 antibody, is approved for the treatment of patients (pts) with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair (MMR) deficient colorectal cancer, both as firs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f10a4651235e2a1fa13a0d027d1dcfba
https://doi.org/10.1200/jco.2021.39.15_suppl.3564
https://doi.org/10.1200/jco.2021.39.15_suppl.3564